Trials / Conditions / ERBB2 Gene Amplification
ERBB2 Gene Amplification
5 registered clinical trials studyying ERBB2 Gene Amplification — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors NCT07361562 | Cogent Biosciences, Inc. | Phase 1 |
| Completed | S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally NCT03365882 | SWOG Cancer Research Network | Phase 2 |
| Active Not Recruiting | Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or NCT03065387 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer NCT02004769 | Sun Yat-sen University | Phase 2 |
| Completed | Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer NCT00006089 | National Cancer Institute (NCI) | Phase 2 |